AFMD - Affimed N.V.
| Previous Close | 2.9600 |
| Open | 2.9600 |
| Bid | 3.0300 x 800 |
| Ask | 3.1000 x 4000 |
| Day's Range | 2.9500 - 3.0800 |
| 52 Week Range | 2.1800 - 4.6800 |
| Volume | 2,441,731 |
| Avg. Volume | 830,754 |
| Market Cap | 230.208M |
| Beta (5Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7170 |
| Earnings Date | Nov. 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.92 |
- GlobeNewswire
Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
Dr. Harstrick, formerly Chief Medical Officer at Molecular Partners and Senior Vice President Medical Sciences and Product Lead for Erbitux® at ImClone Systems/Eli Lilly, will.
- Thomson Reuters StreetEvents
Edited Transcript of AFMD earnings conference call or presentation 19-Nov-19 1:30pm GMT
Q3 2019 Affimed NV Earnings Call
- GlobeNewswire
Affimed Announces Addition to NASDAQ Biotechnology Index
Heidelberg, Germany, December 17, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight.
- Zacks
New Strong Sell Stocks for November 27th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Simply Wall St.
Affimed N.V. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Affimed N.V. (NASDAQ:AFMD) shares fell 3.6% to US$2.38 in the week since its latest third-quarter results. Sales were...
- Zacks
Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -35.71% and -65.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress
FOR IMMEDIATE RELEASE First patient dosed in company’s first registration-directed study of AFM13 for patients with relapsed/refractory peripheral T cell lymphoma.
- GlobeNewswire
Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019
Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to.
- GlobeNewswire
Affimed to Present at the Jefferies 2019 London Healthcare Conference
Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to.
- GlobeNewswire
Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares
Affimed N.V. (“Affimed” or the “Company”) (AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced public offering of 12,000,000 common shares, at the public offering price of $2.50 per share, and the exercise in full by the underwriters of their option to purchase an additional 1,800,000 common shares. The exercise of the option to purchase additional shares brought the total number of common shares sold by Affimed to 13,800,000 common shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by Affimed, to $34.5 million.
- GlobeNewswire
Affimed Announces Pricing of Public Offering of Common Shares
Affimed N.V. (“Affimed” or the “Company”) (AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 12,000,000 of its common shares at a public offering price of $2.50 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 common shares at the public offering price less underwriting discounts.
- GlobeNewswire
Affimed Announces Proposed Public Offering of Common Shares
Affimed N.V. (“Affimed” or the “Company”) (AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has commenced an underwritten public offering of its common shares. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of common shares sold in connection with the offering. Jefferies LLC and SVB Leerink LLC are acting as joint book-running managers of the offering.
- GlobeNewswire
Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers
Activation of innate immunity to target EGFR-expressing solid tumors has potential to address limitations associated with currently available EGFR-targeted therapiesInitiation.
- GlobeNewswire
Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech
Genentech exercises its final option for an exclusive target selection under ongoing, multi-program strategic oncology collaborationThe exclusive target selection triggers a.
- Zacks
Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Imagine Owning Affimed (NASDAQ:AFMD) And Wondering If The 35% Share Price Slide Is Justified
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to...
- GlobeNewswire
Affimed Reports Progress on Key Clinical Development Programs
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1/2a study of AFM24. The initial goal of the study is to determine the maximum tolerated dose and recommended Phase 2 dose of AFM24, as well as to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced cancers known to express the epidermal growth factor receptor, EGFR.
- Thomson Reuters StreetEvents
Edited Transcript of AFMD earnings conference call or presentation 7-Aug-19 12:30pm GMT
Q2 2019 Affimed NV Earnings Call
- Simply Wall St.
Is Affimed (NASDAQ:AFMD) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GlobeNewswire
Affimed to Participate in Investor Conferences in September
Heidelberg, Germany, August 28, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to.
Motley FoolAffimed N.V. (AFMD) Q2 2019 Earnings Call Transcript
AFMD earnings call for the period ending June 30, 2019.
- Zacks
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0.00% and -30.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Affimed Reports Second Quarter 2019 Financial and Operational Results
Heidelberg, Germany, August 7, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight.
- GlobeNewswire
Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host a conference call on Wednesday, August 7, 2019 at 8:30 a.m. ET to discuss its second quarter 2019 financial results and recent corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 917 7200 178 for U.S. callers, or +44 (0) 203 0095710 for international callers, and reference conference ID 9396039 approximately 15 minutes prior to the call.
- Simply Wall St.
Is Affimed N.V.'s (NASDAQ:AFMD) CEO Salary Justified?
Adi Hoess became the CEO of Affimed N.V. (NASDAQ:AFMD) in 2011. This analysis aims first to contrast CEO compensation...
